Phreesia (NYSE:PHR) Posts Earnings Results, Beats Estimates By $0.04 EPS

Phreesia (NYSE:PHR) announced its earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04, Briefing.com reports. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. During the same period in the prior year, the firm earned ($0.58) EPS. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis.

Phreesia Stock Performance

Shares of NYSE PHR traded down $0.10 during midday trading on Monday, reaching $21.63. 550,350 shares of the company were exchanged, compared to its average volume of 444,021. Phreesia has a 1 year low of $17.07 and a 1 year high of $29.16. The stock has a fifty day simple moving average of $20.28 and a 200 day simple moving average of $21.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. DA Davidson reiterated a “buy” rating and issued a $32.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Robert W. Baird increased their price target on Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a report on Friday, September 27th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $34.00 price target on shares of Phreesia in a report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Phreesia has a consensus rating of “Moderate Buy” and an average price target of $29.42.

Insider Buying and Selling at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,212 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $25,488.36. Following the sale, the general counsel now directly owns 119,791 shares in the company, valued at approximately $2,519,204.73. The trade was a 1.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Yvonne Hui sold 2,791 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.92, for a total transaction of $58,387.72. Following the completion of the sale, the insider now owns 27,228 shares in the company, valued at $569,609.76. This represents a 9.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,596 shares of company stock worth $1,518,892. 5.80% of the stock is currently owned by insiders.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.